Spero Therapeutics Inc (SPRO) Institutional Ownership Tracker (Q2 2026)

SPRO ranks #5600 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

SPRO is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

63 institutions disclose a position in SPRO, but none treat it as a major bet — even GSK plc, its most concentrated holder, allocates just 3.4% of its own portfolio to it.

Susquehanna International Group, LLP has added to its SPRO position for two straight quarters, increasing it by $1.1M to reach $1.8M today.

Ken Griffin has trimmed its SPRO position for two straight quarters, cutting it by $952.4K while still holding $145.0K.

SPRO is up 1.7% today, and institutions have been net buyers of $3.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

SPRO posted net income of $7.4M over the trailing twelve months, and currently trades at a P/E of 9.8.

• Profitable — net income of $7.4M over the trailing twelve months
• Revenue grew 9647.3% year over year
• Net income improved year over year, from -$53.6M to $7.4M
• Operating cash flow was negative, using $12.6M in cash
• Current ratio of 7.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.17x equity — within a conventional range